Upsher-Smith Introduces KYMBEE™ for Duchenne Muscular Dystrophy
Upsher-Smith Laboratories, LLC, a key player in the pharmaceutical industry, has officially announced the launch of KYMBEE™ (deflazacort) Tablets. This innovative pharmaceutical product is specifically indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are five years of age and older. Produced in the United States, KYMBEE™ stands out as the only deflazacort that is fortified by the company’s unique Promise of Support Program, offering crucial aid to families during their treatment journeys.
About the Treatment
KYMBEE™ Tablets come in multiple strengths, including 6 mg, 18 mg, 30 mg, and 36 mg, providing flexibility for prescribers aiming to tailor treatments to individual needs. This medication is primarily distributed through Orsini Specialty Pharmacy, known for its expertise in rare diseases and specialized therapy solutions.
Addressing Treatment Challenges
In a statement by Michelle Zachman, PharmD, BCPS, BCMAS, the Medical Affairs Director at Upsher-Smith, the company is acutely aware of the hurdles families face when trying to access medications for DMD. The introduction of KYMBEE™, along with the Promise of Support Program, symbolizes their commitment to lightening the burden for families navigating the complexities associated with accessing critical treatments.
Promise of Support Program
The dedicated Promise of Support Program for KYMBEE™ is crafted to assist families throughout their treatment journey. The program includes:
- Copay assistance to help manage out-of-pocket expenses*
- Guidance on navigating insurance coverage
- Access pathways to therapy even when insurance challenges emerge
- A dedicated support team available to answer questions
*Certain limitations may apply.
Information for Families and Prescribers
Families are encouraged to discuss KYMBEE™ with their healthcare providers. Upsher-Smith is readily available for queries and concerns, reachable at 1-888-650-3789.
Important Safety Information
Before starting KYMBEE™, it’s crucial to understand some important safety information. Certain individuals should avoid this medication:
- Those who have had hypersensitivity or allergic reactions to deflazacort or its inactive components.
Several critical considerations must be discussed with healthcare providers:
- KYMBEE™ may alter hormone functions, and abrupt withdrawal could lead to life-threatening adrenal insufficiency.
- The risk of infections increases when administering KYMBEE™; patients should monitor for any infections closely.
- There could be an increase in blood pressure and water retention.
- Behavioral and mood alterations can occur, requiring immediate medical attention if symptoms arise.
Additionally, there are risks associated with long-term use, including osteoporosis and potential eye complications.
For a comprehensive understanding of the potential risks and benefits of KYMBEE™, patients should consult the prescribing information and discuss their specific health circumstances with healthcare professionals.
Understanding Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting young boys. The condition affects approximately 15,000 individuals in the U.S. and around 300,000 globally. Diagnoses often occur around the age of four, highlighting the urgency for effective treatments such as KYMBEE™. While there is no cure, early intervention through therapy, medications, and support can significantly slow the disease's progression.
About Upsher-Smith Laboratories, LLC
Upsher-Smith Laboratories is committed to providing high-quality pharmaceutical products aimed at improving patient health. They continuously strive for excellence and sustainable growth. As a part of the Bora Group, Upsher-Smith leverages robust industry relationships to ensure a steady supply of medications across a broad spectrum of healthcare providers.
Frequently Asked Questions
What is KYMBEE™ used for?
KYMBEE™ is indicated for the treatment of Duchenne muscular dystrophy in patients aged 5 and older.
What is the Promise of Support Program?
The Promise of Support Program provides assistance with copays, insurance navigation, access to therapy, and support from a dedicated team for families.
How can families access information about KYMBEE™?
Families can contact Upsher-Smith at 1-888-650-3789 for any questions or concerns regarding KYMBEE™.
What are the potential side effects of KYMBEE™?
Common side effects may include weight gain, increased appetite, and mood changes. Consultation with a healthcare provider is advised for more details.
Is KYMBEE™ safe for all patients?
No, certain individuals should not take KYMBEE™; it is essential to discuss personal health conditions with healthcare providers.
